Radioenhanced camptothecin derivative cancer treatments
US6281223A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 13, 1999 |
| Grant date | Aug 28, 2001 |
| Priority date | — |
| Expiry date | Apr 13, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including coadministering the radiation and an orally dosed camptothecin derivative to the host being treated for cancer. Also disclosed is a method of enhancing the therapeutic effect of radiation in a host being treated for cancer including orally dosing the host being treated for cancer with a camptothecin derivative; and administering radiation at a point when a serum concentration of the camptothecin derivative in the host being treated for cancer reaches about 50% or more of the maximum concentration achieved by the oral dose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.